Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 3
1(33.3%)
3Total
Phase 2(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03470441Phase 2Completed

A Study of Acute Myocardial Infarction Using FDY-5301

Role: lead

NCT04837001Phase 3Completed

Evaluation in STEMI Patients Using FDY-5301

Role: lead

NCT04430283Phase 2Terminated

Evaluation of FDY-5301 in Major Trauma Patients in ICU

Role: lead

All 3 trials loaded